Glucosamine sulphate in the treatment of knee osteoarthritis: Cost-effectiveness comparison with paracetamol

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 756-762

  Scholtissen, S ^a   Bruyere O ^a   Neuprez, A ^a   Severens, J L ^b,c   Herrero Beaumont, G ^d   Rovati, L ^e   Hiligsmann, M ^a   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e Department of Clinical Pharmacology ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE SULFATE; IBUPROFEN; PARACETAMOL; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TABLET; TREATMENT DURATION;

ACETAMINOPHEN; ANTI-INFLAMMATORY AGENTS; COST-BENEFIT ANALYSIS; FEMALE; GLUCOSAMINE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 77950645209     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02362.x     Document Type: Article

References (28)

1. Bijlsma JW, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol 2007 21 : 59 76.
2. Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008 9 : 165.
3. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 62 : 1145 1155.
4. Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005 2 : CD002946.
5. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000 283 : 1469 1475.
6. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007 56 : 2267 2277.
7. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003 163 : 1514 1522.
8. Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007 56 : 2105 2110.
9. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007 56 : 555 567.
10. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine Sulfate Use and Delay of Progression of Knee Osteoarthritis: a 3-Year, Randomized, Placebo-Controlled, Double-blind Study. Arch Intern Med 2002 162 : 2113 2123.
11. Reginster JY, Deroisy R, Rovati LC et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001 357 : 251 256.
12. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988 15 : 1833 1840. (Pubitemid 19037656)
13. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health and Quality of Life Outcomes 2003 1 : 54. (Pubitemid 39111942)
14. Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW. A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J Rheumatol 2007 34 : 534 542. (Pubitemid 46364008)
15. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials.
16. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, S GL. Methods for the Economic Evaluation of Health Care Programmes.
17. Lekkerkerker F, Kanis JA, Alsayed N et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007 18 : 1311 1317. (Pubitemid 47389473)
18. IMS. Intercontinental Marketing Services. http://www.imshealth.com (accessed June 2009).
19. Black W. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990 10 : 212 214. (Pubitemid 20311440)
20. Efron B, Tibshirani RJ. An Introduction to the Bootstrap.
21. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ 2004 13 : 405 415. (Pubitemid 38660390)
22. NICE. Guide to the Methods of Health Technology Appraisal.
23. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998 13 : 716 717.
24. Severens JL, Brunenberg DEM, Fenwick EAL, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and reluctance to lose. PharmacoEconomics 2005 23 : 1207 1214. (Pubitemid 41803317)
25. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 1995 8 : 245 252.
26. Graf von der Schulenburg JM, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharamceuticals. HEPAC 2000 1 : 2 8.
27. Barton G, Sach T, Jenkinson C, Avery A, Doherty M, Muir K. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health and Quality of Life Outcomes 2008 6 : 51.
28. Marshall D, Pericak D, Grootendorst P et al. Validation of a prediction model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip. Value in Health 2008 11 : 470 477. (Pubitemid 351712972)